pca 4230 has been researched along with colforsin in 1 studies
| Studies (pca 4230) | Trials (pca 4230) | Recent Studies (post-2010) (pca 4230) | Studies (colforsin) | Trials (colforsin) | Recent Studies (post-2010) (colforsin) |
|---|---|---|---|---|---|
| 9 | 0 | 0 | 13,460 | 46 | 1,298 |
| Protein | Taxonomy | pca 4230 (IC50) | colforsin (IC50) |
|---|---|---|---|
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 1.729 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.041 | |
| Adenylate cyclase type 1 | Homo sapiens (human) | 0.0955 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aragonés, MD; Catalán, RE; Lombardía, M; Martínez, AM | 1 |
1 other study(ies) available for pca 4230 and colforsin
| Article | Year |
|---|---|
Involvement of cyclic GMP in the mode of action of a new antithrombotic agent PCA-4230; inhibition of the platelet cyclic GMP dependent phosphodiesterase.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Colforsin; Cyclic AMP; Cyclic GMP; Dihydropyridines; Drug Synergism; Fibrinolytic Agents; Kinetics; Nitroprusside; Phosphodiesterase Inhibitors; Phosphorylation; Rabbits; Serotonin; Thrombin; Vasodilator Agents | 1997 |